TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
22 Junho 2023 - 8:00AM
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology
company committed to more effectively treating cancer using RNA
therapeutics, announced today publication of new data relevant to
its lead therapeutic candidate, TTX-MC138, in the Journal of
Clinical Oncology. The abstract, published in the June 1
supplemental issue of the journal, was presented at the 2023 Annual
Meeting of the American Society of Clinical Oncology (ASCO).
The study shows that inhibition of microRNA-10b,
the therapeutic target of TTX-MC138, in breast cancer cells
impaired the capacity of cancer stem cells to create new tumors and
become metastatic. TransCode believes that these findings are
important because cancer stem cells have long been known to play a
critical role in cancer initiation, metastasis, recurrence, and
resistance to therapy. Therefore, inhibiting the tumor-promoting
capacity of these cells using TTX-MC138 could improve outcomes in
patients with breast cancer that is recurrent and resistant to
treatment.
TTX-MC138 is designed to inhibit the oncogenic
RNA, microRNA-10b, described as the master regulator of cancer
progression in a number of advanced solid tumors, including breast
cancer. TransCode believes that TTX-MC138 could be used as a
treatment for many of these cancers. In a preclinical model of
pancreatic adenocarcinoma, administration of TTX-MC138 as
monotherapy resulted in complete responses, manifested as
regression without recurrence, in 40% of treated animals. This
study comes on the heels of preclinical studies in human breast
cancer in animals demonstrating complete regressions of metastatic
disease. In addition to murine models of cancer, TTX-MC138 was
successfully delivered and demonstrated preliminary efficacy in a
case study of spontaneous feline mammary carcinoma.
TransCode Therapeutics recently received FDA and
IRB approval for a first-in-human clinical trial with TTX-MC138 in
patients with advanced solid cancers. In this clinical trial, up to
12 patients will be given a single dose of radiolabeled TTX-MC138
followed by noninvasive positron emission tomography-magnetic
resonance imaging (PET-MRI). The trial is intended to quantify the
amount of TTX-MC138 delivered to metastatic lesions and the
pharmacokinetics of the therapeutic candidate in cancer patients.
The trial could yield critical data regarding therapeutic dose,
timing, and potential safety that could inform later stage clinical
trials and further advance TTX-MC138 as a therapeutic candidate
against glioblastoma and other advanced malignancies. This trial is
not intended to demonstrate any therapeutic effect.
TransCode Therapeutics’ Chief Executive Officer,
Michael Dudley, commented “These new results provide insight into
why TTX-MC138 is so effective in multiple preclinical cancer models
and has frequently demonstrated complete responses with no
recurrence in the metastatic cancer setting”. The Journal
of Clinical Oncology is the primary forum of
scientific discourse for ASCO and is the foremost
peer-reviewed journal focusing on clinical cancer research and an
authoritative source for current information on the diagnosis and
treatment of patients with cancer.
About TransCode Therapeutic
TransCode is an RNA oncology company created on
the belief that cancer can be more effectively treated using RNA
therapeutics. The Company has created a platform of drug candidates
designed to target a variety of tumor types with the objective of
significantly improving patient outcomes. The Company’s lead
therapeutic candidate, TTX-MC138, is focused on treating metastatic
cancer, which is believed to cause approximately 90% of all cancer
deaths totaling over nine million per year worldwide. The Company
believes that TTX-MC138 has the potential to dramatically improve
clinical outcomes in a range of cancers, including breast,
pancreatic, ovarian and colon cancer, glioblastomas and others. Two
of the Company’s other drug candidates, TTX-siPDL1 and
TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and
LIN28B, respectively. TransCode also has three cancer-agnostic
programs: TTX-RIGA, an RNA–based agonist of the retinoic
acid-inducible gene I designed to drive an immune response in the
tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy
platform for the repair or elimination of cancer-causing genes
inside tumor cells; and TTX-mRNA, an mRNA-based platform for the
development of cancer vaccines designed to activate cytotoxic
immune responses against tumor cells.
Forward-Looking Statements
This release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including, without limitation, statements
concerning the results of a preclinical study of TTX-MC138 in
breast cancer and other tumor types, statements concerning expected
clinical results of TransCode’s therapeutic candidates, statements
concerning the results of RNA research, statements concerning the
potential for treating cancer with RNA therapeutics, statements
concerning the timing and outcome of expected regulatory filings
and clinical trials, including the planned first-in-human study of
TTX-MC138, statements concerning the timing and outcome of this
study, including whether this study will demonstrate
proof-of-mechanism, and statements concerning TransCode’s
development programs and TTX technology platform generally. Of
note, a Phase 0 clinical trial is an exploratory study, conducted
under an exploratory Investigational New Drug (eIND) application.
Exploratory IND studies usually involve very limited human exposure
to a therapeutic candidate to evaluate mechanism of action in order
to inform potential clinical evaluation in future clinical studies,
but otherwise have no therapeutic intent. Any forward-looking
statements in this press release are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: the risk associated with drug discovery and
development; the risk that the results of our planned clinical
trials will not be consistent with our pre-clinical studies or
expectations; risks associated with the timing and outcome of
TransCode’s planned regulatory submissions; risks associated with
TransCode’s planned clinical trials for its product candidates;
risks associated with obtaining, maintaining and protecting
intellectual property; risks associated with TransCode’s ability to
enforce its patents against infringers and defend its patent
portfolio against challenges from third parties; the risk of
competition from other companies developing products for similar
uses; risks associated with TransCode’s financial condition and its
need to obtain additional funding to support its business
activities, including TransCode’s ability to continue as a going
concern; risks associated with TransCode’s dependence on third
parties; and risks associated with the COVID-19 coronavirus. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause TransCode’s actual
results to differ from those contained in or implied by the
forward-looking statements, see the section entitled “Risk Factors”
in TransCode’s Annual Report on Form 10-K for the year ended
December 31, 2022, as well as discussions of potential risks,
uncertainties and other important factors in any subsequent
TransCode filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release;
TransCode undertakes no duty to update this information unless
required by law.
For more information, please
contact:
TransCode Therapeutics, Inc.Alan Freidman, VP Investor
Relationsalan.freidman@transcodetherapeutics.com
TransCode Therapeutics (NASDAQ:RNAZ)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
TransCode Therapeutics (NASDAQ:RNAZ)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024